Clinical practice guidelines for the management of invasive Candida infections in adults in the Middle East region: Expert panel recommendations

Journal of Infection and Public Health

Volumn 7, Issue 1, 2014, Pages 6-19

  Alothman, Adel F ^a   Al Musawi, Tariq ^b   Al Abdely, Hail M ^c   Salman, Jameela Al ^d   Almaslamani, Muna ^e   Yared, Nadine ^f   Butt, Adeel A ^g   Raghubir, Nirvana ^h   Morsi, Waleed El ^h   Al Thaqafi, Abdulhakeem O ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b SAAD SPECIALIST HOSPITAL   (Saudi Arabia)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d SALMANIYA MEDICAL COMPLEX   (Bahrain)

^e HAMAD MEDICAL CORPORATION   (Qatar)

^f LEBANESE UNIVERSITY   (Lebanon)

^g SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^h PFIZER INC   (United States)

Author keywords

Candida; Candidiasis; Guidelines; Middle East; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; TRIAZOLE; VORICONAZOLE;

BACTERIAL ARTHRITIS; CANDIDA ENDOCARDITIS; CANDIDA ENDOPHTHALMITIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDIASIS; CLINICAL DECISION MAKING; CRITICALLY ILL PATIENT; CYSTITIS; FUNGUS BALL; HUMAN; INVASIVE CANDIDIASIS; MIDDLE EAST; MORBIDITY; MORTALITY; NEUTROPENIA; OSTEOMYELITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PYELONEPHRITIS; REVIEW; TREATMENT DURATION;

ABCD; ABLC; AMB; AMB DEOXYCHOLATE; AMB-D; AMMI; AMPHOTERICIN B; AMPHOTERICIN B COLLOIDAL DISPERSION; AMPHOTERICIN B LIPID COMPLEX; ASSOCIATION OF MEDICAL MICROBIOLOGY AND INFECTIOUS DISEASE; BLOOD STREAM INFECTION; BSI; C. ALBICANS GERM-TUBE ANTIBODIES; CAGTA; CANDIDA; CANDIDIASIS; ECCMID; ECIL4; EORTC/MSG; EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES; EUROPEAN COUNCIL ON INFECTIONS IN LEUKAEMIA; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER/INVASIVE FUNGAL INFECTIONS COOPERATIVE GROUP AND THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES MYCOSES STUDY GROUP; GUIDELINES; ICU; IDSA; INFECTIOUS DISEASE SOCIETY OF AMERICA; INTENSIVE CARE UNIT; L-AMB; LFAMB; LIPID FORMULATION AMB; LIPOSOMAL AMB; MIDDLE EAST; TREATMENT;

ADULT; ASPERGILLOSIS; CANDIDIASIS, INVASIVE; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84892891294     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2013.08.002     Document Type: Review

References (52)

1. McNeil M.M., Nash S.L., Hajjeh R.A., Phelan M.A., Conn L.A., Plikaytis B.D., Warnock D.W. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001, 33:641-647.
2. Fridkin S.K., Jarvis W.R. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996, 9:499-511.
3. Rangel-Frausto M.S., Wiblin T., Blumberg H.M., Saiman L., Patterson J., Rinaldi M., et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999, 29:253-258.
4. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
5. Morgan J., Meltzer M.I., Plikaytis B.D., Sofair A.N., Huie-White S., Wilcox S., et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005, 26:540-547.
6. Bow E.J., Evans G., Fuller J., Laverdiere M., Rotstein C., Rennie R., et al. Canadian clinical practice guidelines for invasive candidiasis in adults. Can J Infect Dis Med Microbiol 2010, 21:e122-e150.
7. Pagano L., Lumb J. Update on invasive fungal disease. Future Microbiol 2011, 6:985-989.
8. Raoul H., Ursula F., Bertrand G., Patricia R., Anne T., Catherine C. Antifungal therapy in leukemia patients 2011.
9. Thursky K.A., Playford E.G., Seymour J.F., Sorrell T.C., Ellis D.H., Guy S.D., et al. Recommendations for the treatment of established fungal infections. Intern Med J 2008, 38:496-520.
10. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.
11. Tortorano A.M., Kibbler C., Peman J., Bernhardt H., Klingspor L., Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006, 27:359-366.
12. Al-Tawfiq J.A. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996-2004. Int J Infect Dis 2007, 11:239-244.
13. Ellis M., Hedstrom U., Jumaa P., Bener A. Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995-2001. Med Mycol 2003, 41:521-528.
14. Hassan I., Powell G., Sidhu M., Hart W.M., Denning D.W. Excess mortality, length of stay and cost attributable to candidaemia. J Infect 2009, 59:360-365.
15. Akbar D.H., Tahawi A.T. Candidemia at a University Hospital: epidemiology, risk factors and predictors of mortality. Ann Saudi Med 2001, 21:178-182.
16. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ellis D., Tullio V., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997-2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010, 48:1366-1377.
17. Ruhnke M., Rickerts V., Cornely O.A., Buchheidt D., Glockner A., Heinz W., et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 2011, 54:279-310.
18. Peman J., Zaragoza R. Current diagnostic approaches to invasive candidiasis in critical care settings. Mycoses 2010, 53:424-433.
19. de Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
20. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002, 49(Suppl. 1):37-41.
21. Walsh T.J., Hiemenz J.W., Seibel N.L., Perfect J.R., Horwith G., Lee L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998, 26:1383-1396.
22. Wingard J.R. Lipid formulations of amphotericins: are you a lumper or a splitterα. Clin Infect Dis 2002, 35:891-895.
23. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366:1435-1442.
24. Kontoyiannis D.P., Bodey G.P., Mantzoros C.S. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 2001, 44:125-135.
25. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., van der Horst C.M., Edwards J.E., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994, 331:1325-1330.
26. Rex J.H., Pappas P.G., Karchmer A.W., Sobel J., Edwards J.E., Hadley S., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221-1228.
27. Eichel M., Just-Nubling G., Helm E.B., Stille W. Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis. Mycoses 1996, 39(Suppl. 1):102-106.
28. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029.
29. Kuse E.R., Chetchotisakd P., da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527.
30. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482.
31. Shorr A.F., Wu C., Kothari S. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei. J Antimicrob Chemother 2011, 66:375-380.
32. Andes D.R., Safdar N., Baddley J.W., Playford G., Reboli A.C., Rex J.H., et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012, 54:1110-1122.
33. Pappas P.G., Rotstein C.M., Betts R.F., Nucci M., Talwar D., de Waele J.J., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.
34. Betts R., Glasmacher A., Maertens J., Maschmeyer G., Vazquez J.A., Teppler H., et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006, 106:466-473.
35. Kanji J.N., Laverdiere M., Rotstein C., Walsh T.J., Shah P.S., Haider S. Treatment of invasive Candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials. Leuk Lymphoma 2013, 24(7):1479-1487.
36. Nguyen M.H., Peacock J.E., Tanner D.C., Morris A.J., Nguyen M.L., Snydman D.R., et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995, 155:2429-2435.
37. Luzzati R., Amalfitano G., Lazzarini L., Soldani F., Bellino S., Solbiati M., et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur J Clin Microbiol Infect Dis 2000, 19:602-607.
38. Nucci M., Anaissie E., Betts R.F., Dupont B.F., Wu C., Buell D.N., et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010, 51:295-303.
39. Guery B.P., Arendrup M.C., Auzinger G., Azoulay E., Borges Sa M., Johnson E.M., et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II Treatment. Intens Care Med 2009, 35:206-214.
40. Thaler M., Pastakia B., Shawker T.H., O'Leary T., Pizzo P.A. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988, 108:88-100.
41. Walsh T.J., Whitcomb P.O., Revankar S.G., Pizzo P.A. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995, 76:2357-2362.
42. Gokhale P.C., Barapatre R.J., Advani S.H., Kshirsagar N.A., Pandya S.K. Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report. J Cancer Res Clin Oncol 1993, 119:569-571.
43. Anaissie E., Bodey G.P., Kantarjian H., David C., Barnett K., Bow E., et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991, 91:142-150.
44. Kauffman C.A., Bradley S.F., Ross S.C., Weber D.R. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991, 91:137-141.
45. Sanchez-Portocarrero J., Perez-Cecilia E., Corral O., Romero-Vivas J., Picazo J.J. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 2000, 37:169-179.
46. Nguyen M.H., Yu V.L. Meningitis caused by Candida species: an emerging problem in neurosurgical patients. Clin Infect Dis 1995, 21:323-327.
47. Voice R.A., Bradley S.F., Sangeorzan J.A., Kauffman C.A. Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clin Infect Dis 1994, 19:60-66.
48. Geers T.A., Gordon S.M. Clinical significance of Candida species isolated from cerebrospinal fluid following neurosurgery. Clin Infect Dis 1999, 28:1139-1147.
49. Groll A.H., Giri N., Petraitis V., Petraitiene R., Candelario M., Bacher J.S., et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000, 182:274-282.
50. Al-Hedaithy S.S. The yeast species causing fungemia at a university hospital in Riyadh, Saudi Arabia, during a 10-year period. Mycoses 2003, 46:293-298.
51. Bukharie H.A. Nosocomial candidemia in a tertiary care hospital in Saudi Arabia. Mycopathologia 2002, 153:195-198.
52. Khan Z.U., Chugh T.D. Invasive fungal infections in Kuwait: a retrospective study. Indian J Chest Dis Allied Sci 2000, 42:279-287.